5,986 Shares in IQVIA Holdings Inc. $IQV Acquired by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the SEC. The firm purchased 5,986 shares of the medical research company’s stock, valued at approximately $1,157,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. BlackRock Inc. purchased a new stake in IQVIA in the second quarter valued at approximately $2,811,292,000. Geode Capital Management LLC raised its holdings in shares of IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners raised its stake in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after buying an additional 530,672 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after acquiring an additional 528,753 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $260.17 on Monday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market cap of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18. The stock has a 50-day moving average of $213.32 and a two-hundred day moving average of $187.21. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $260.40.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 over the last quarter. Corporate insiders own 1.70% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent analyst reports. Barclays restated an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Mizuho lifted their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Stifel Nicolaus raised their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Finally, HSBC reaffirmed a “buy” rating and set a $240.00 target price on shares of IQVIA in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.